TY - JOUR
T1 - Global Efforts in the Development of Vaccines for Tuberculosis
T2 - Requirements for Improved Vaccines Against Mycobacterium tuberculosis
AU - Méndez-Samperio, P.
N1 - Publisher Copyright:
© 2016 The Foundation for the Scandinavian Journal of Immunology
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Currently, more than 9.0 million people develop acute pulmonary tuberculosis (TB) each year and about 1.5 million people worldwide die from this infection. Thus, developing vaccines to prevent active TB disease remains a priority. This article discusses recent progress in the development of new vaccines against TB and focusses on the main requirements for development of improved vaccines against Mycobacterium tuberculosis (M. tb). Over the last two decades, significant progress has been made in TB vaccine development, and some TB vaccine candidates have currently completed a phase III clinical trial. The potential public health benefits of these vaccines are possible, but it will need much more effort, including new global governance investment on this research. This investment would certainly be less than the annual global financial toll of TB treatment.
AB - Currently, more than 9.0 million people develop acute pulmonary tuberculosis (TB) each year and about 1.5 million people worldwide die from this infection. Thus, developing vaccines to prevent active TB disease remains a priority. This article discusses recent progress in the development of new vaccines against TB and focusses on the main requirements for development of improved vaccines against Mycobacterium tuberculosis (M. tb). Over the last two decades, significant progress has been made in TB vaccine development, and some TB vaccine candidates have currently completed a phase III clinical trial. The potential public health benefits of these vaccines are possible, but it will need much more effort, including new global governance investment on this research. This investment would certainly be less than the annual global financial toll of TB treatment.
UR - http://www.scopus.com/inward/record.url?scp=84988599457&partnerID=8YFLogxK
U2 - 10.1111/sji.12465
DO - 10.1111/sji.12465
M3 - Artículo de revisión
SN - 0300-9475
VL - 84
SP - 204
EP - 210
JO - Scandinavian Journal of Immunology
JF - Scandinavian Journal of Immunology
IS - 4
ER -